Keywords
Pediatric
corticosteroids
How to Cite
Abstract
The aim of this report is to describe a 3-year-old patient with global developmental delay, history of chronic malnutrition, broncho-obstructive syndrome and idiopathic hypereosinophilic síndrome of one year of evolution. The most common causes of eosinophilia are discarded: reactive (drug induced, inflammatory, allergic, infectious, neoplastic disorders, autoimmune, endocrinopathy disease) and familial or clonal eosinophilia. His corticosteroid dependence poses treatment challenges. Today the patient is under treatment with meprednisone 0.75 mg/kg/day associated with hydroxyurea 20 mg/kg/day with good evolution.
References
Fischman Laura A y col. Síndrome Hipereosinofílico. HEMATOLOGÍA. 2007;11(3):220-242.
Butt NM, Lambert J, Ali S et al; British Committee for Standards in Haematology. Guideline for the investigation and management of eosinophilia. Br J Haematol. 2017 Feb;176(4):553-572. doi: 10.1111/bjh.14488.
Mikhail ES, Ghatol A. Hypereosinophilic Syndrome.2024 Jan 11. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
Klion AD. How I treat hypereosinophilic syndromes. Blood. 2015 Aug 27;126(9):1069-77. doi: 10.1182/blood-2014-11-551614.
Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis. 2007 Sep 11;2:37. doi: 10.1186/1750-1172-2-37.
Klion AD, Bochner BS, Gleich GJ et al; The Hypereosinophilic Syndromes Working Group. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol. 2006 Jun;117(6):1292-302. doi: 10.1016/j.jaci.2006.02.042.
Klion A. Hypereosinophilic syndrome: approach to treatment in the era of precision medicine. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):326-331. doi: 10.1182/asheducation-2018.1.326.
Hwee J, Huynh L, Du S et al. Hypereosinophilic syndrome in Europe: Retrospective study of treatment patterns, clinical manifestations, and healthcare resource utilization. Ann Allergy Asthma Immunol. 2023 Jun;130(6):768-775. doi: 10.1016/j.anai.2023.02.022.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar